Form 4: Director Gary Lyons Acquires Travere Therapeutics Stock

Director Gary Lyons acquired 4,000 shares of common stock and was granted 12,000 stock options in Travere Therapeutics, Inc. on May 19, 2026.

Summary

• Director Gary Lyons acquired 4,000 shares of Travere Therapeutics, Inc. common stock on May 19, 2026.
• The acquisition was made at a price of $0 per share, indicating it was likely an equity grant.
• Following this transaction, Mr. Lyons beneficially owns 61,500 shares of common stock.
• Additionally, Mr. Lyons was granted 12,000 stock options with an exercise price of $42.26 per share.
• These stock options are exercisable starting May 19, 2027, and expire on May 19, 2036.
• The equity award, including the options, vests over a one-year period.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, indicating standard director compensation practices and continued insider ownership, but without new financial performance data.

Positives

• Director Gary Lyons increased his beneficial ownership of Travere Therapeutics stock.
• The acquisition of 4,000 shares and 12,000 stock options suggests continued alignment of management and director interests with shareholders.
• The stock options have a strike price of $42.26, indicating a potential for future value appreciation if the stock price exceeds this level.

Negatives

• The filing does not contain any negative information regarding financial performance or operational issues.

Risks

• The value of the stock options is contingent on the future performance of Travere Therapeutics' stock price.
• The vesting schedule for the equity award means the full benefit of the grant is realized over time.

Future Outlook

The grant of stock options with an exercise price of $42.26 and a vesting period suggests management's expectation of future stock price appreciation.

Industry Context

StockSavvy.ai notes that insider grants of stock and options are common in the biotechnology sector as a means to attract and retain key talent and align their financial interests with long-term company performance.

Stakeholder Impact

• Shareholders: The transaction reflects standard compensation for directors and may signal confidence in future stock performance, potentially benefiting shareholders if the stock price increases.

Next Steps

• The equity award vests over a one-year period.
• Stock options become exercisable starting May 19, 2027.

Key Dates

Keywords

Travere Therapeutics, TVTX, Form 4, SEC Filing, Insider Trading, Stock Options, Equity Grant, Director Compensation, Beneficial Ownership